Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Moon

Showing results (51-60 of 105) with videos related to

Pageof 11
Sort By:
Pathology|March 13, 2012
Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysisMichael Kerger, Matthew K H Hong, John Pedersen, et al.
Pathology, Research and Practice|October 17, 2017
3D modelling of radical prostatectomy specimens: Developing a method to quantify tumor morphometry for prostate cancer risk predictionMarcus C Hovens, Kevin Lo, Michael Kerger, et al.
Radiation Oncology (London, England)|February 14, 2024
Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancerMuhammad Ali, Kendrick Koo, David Chang, et al.
BJU International|February 14, 2015
Patients with medical risk factors for chronic kidney disease are at increased risk of renal impairment despite the use of nephron-sparing surgeryPrassannah Satasivam, Fairleigh Reeves, Kenny Rao, et al.
International Journal of Cancer|June 20, 2024
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trialAndrew W See, Paul Conway, Mark Frydenberg, et al.
BJU International|June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinomaMuhammad Ali, Mathias Bressel, David Chang, et al.
Cancers|January 28, 2026
Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical ApplicationsAbdullah Al-Khanaty, Shane Qin, Carlos Delgado, et al.
European Urology|September 20, 2018
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical TrialShankar Siva, Mathias Bressel, Declan G Murphy, et al.
European Urology Open Science|October 3, 2022
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell CarcinomaCristian Udovicich, Jason Callahan, Mathias Bressel, et al.
International Journal of Radiation Oncology, Biology, Physics|June 27, 2025
SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II TrialConstanza Vargas, Joe Carrello, Mathias Bressel, et al.
Pageof 11

Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Pathology|March 13, 2012
Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysisMichael Kerger, Matthew K H Hong, John Pedersen, et al.
Pathology, Research and Practice|October 17, 2017
3D modelling of radical prostatectomy specimens: Developing a method to quantify tumor morphometry for prostate cancer risk predictionMarcus C Hovens, Kevin Lo, Michael Kerger, et al.
Radiation Oncology (London, England)|February 14, 2024
Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancerMuhammad Ali, Kendrick Koo, David Chang, et al.
BJU International|February 14, 2015
Patients with medical risk factors for chronic kidney disease are at increased risk of renal impairment despite the use of nephron-sparing surgeryPrassannah Satasivam, Fairleigh Reeves, Kenny Rao, et al.
International Journal of Cancer|June 20, 2024
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trialAndrew W See, Paul Conway, Mark Frydenberg, et al.
BJU International|June 28, 2025
Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinomaMuhammad Ali, Mathias Bressel, David Chang, et al.
Cancers|January 28, 2026
Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical ApplicationsAbdullah Al-Khanaty, Shane Qin, Carlos Delgado, et al.
European Urology|September 20, 2018
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical TrialShankar Siva, Mathias Bressel, Declan G Murphy, et al.
European Urology Open Science|October 3, 2022
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell CarcinomaCristian Udovicich, Jason Callahan, Mathias Bressel, et al.
International Journal of Radiation Oncology, Biology, Physics|June 27, 2025
SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II TrialConstanza Vargas, Joe Carrello, Mathias Bressel, et al.
Pageof 11